Eliquis Dosage/Direction for Use

Prevention of VTE: elective hip or knee replacement surgery: The recommended dose of ELIQUIS is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery.
In patients undergoing hip replacement surgery, the recommended duration of treatment is 32 to 38 days.
In patients undergoing knee replacement surgery, the recommended duration of treatment is 10 to 14 days.
Prevention of stroke in patients with non-valvular atrial fibrillation (NVAF): The recommended dose of ELIQUIS is 5 mg taken orally twice daily.
Dose reduction: The recommended dose of ELIQUIS is 2.5 mg taken orally twice daily in patients with NVAF and at least two of the following characteristics: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (133 micromole/L).
Therapy should be continued long-term.
If a dose is missed, the patient should take ELIQUIS immediately and then continue with twice daily intake as before.
ELIQUIS can be taken with or without food.
Renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (see Pharmacology: Pharmacokinetics under Actions).
In patients with severe renal impairment (creatinine clearance 15-29 mL/min) the following recommendations apply (see Precautions and Pharmacology: Pharmacokinetics under Actions): Prevention of VTE: elective hip or knee replacement surgery: No dose adjustment is necessary in patients with mild, moderate or severe (creatinine clearance 15-29 mL/min) renal impairment (see Pharmacology: Pharmacokinetics under Actions).
Prevention of stroke: NVAF: Patients should receive the lower dose of apixaban 2.5 mg twice daily.
Patients with serum creatinine ≥1.5 mg/dL (133 micromole/L) associated with age ≥80 years or body weight  ≤60 kg should also receive the lower dose of apixaban 2.5 mg twice daily.
In patients with creatinine clearance <15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore, apixaban is not recommended (see Precautions and Pharmacology: Pharmacokinetics under Actions).
Hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment (see Precautions and Pharmacology: Pharmacokinetics under Actions).
Body weight: Prevention of VTE: elective hip or knee replacement surgery: No dose adjustment required (see Pharmacology: Pharmacokinetics under Actions).
Prevention of stroke: NVAF: No dose adjustment required, unless criteria for dose reduction are met (see Dose reduction).
Gender: No dose adjustment required (see Pharmacology: Pharmacokinetics under Actions).
Paediatric population: The safety and efficacy of ELIQUIS in children below age 18 have not yet been established. No data are available.
Elderly: Prevention of VTE: elective hip or knee replacement surgery: No dose adjustment required (see Pharmacology: Pharmacokinetics under Actions).
Prevention of stroke: NVAF: No dose adjustment required, unless criteria for dose reduction are met (see Dose reduction).
Cardioversion (NVAF): Patients can stay on apixaban while being cardioverted.
Switching: Switching treatment from parenteral anticoagulants to ELIQUIS (and vice versa) can be done at the next scheduled dose (see Interactions). These agents should not be administered simultaneously.
Switching from Vitamin K antagonist (VKA) therapy to Eliquis: When converting patients from Vitamin K antagonist (VKA) therapy to Eliquis, discontinue warfarin or other VKA therapy and start Eliquis when the international normalized ratio (INR) is <2.0.
Switching from Eliquis to VKA therapy: When converting patients from Eliquis to VKA therapy, continue administration of Eliquis for at least 2 days after beginning VKA therapy. After 2 days of coadministration of Eliquis with VKA therapy, obtain an INR prior to the next scheduled dose of Eliquis. Continue co-administration of Eliquis and VKA therapy until the INR is ≥2.0.